Pharmacotherapy Publishing Inc
View my basket
Atypon Link logo

You have no access to this article

Effect of Ginkgo biloba Extract on Plasma Steroid Concentrations in Healthy Volunteers: A Pilot Study


Author(s): John S. Markowitz | C. Lindsay DeVane | John G. Lewis | Kenneth D. Chavin | Jun-Sheng Wang | Jennifer L. Donovan
doi: 10.1592/phco.2005.25.10.1337
Prev | Table of contents | Next
 
View PDF article (58 K) View references
Email this link
 What is RSS?
Trouble viewing articles as PDF?
 
  Pharmacotherapy
 
Print ISSN: 0277-0008
Volume: 25 | Issue: 10
Cover date: October 2005
Page(s): 1337-1340
 
 
  Key Words
 
androgens, ginkgo biloba, EGb 761, endogenous steroids, supplement
 
  Abstract

Study Objective. To determine if a standardized ginkgo supplement significantly alters concentrations of circulating androgenic steroids in humans.

Design. Open-label, fixed–treatment order, crossover study.

Setting. University general clinical research center.

Subjects. Eleven healthy volunteers (six men, five women).

Intervention. Volunteers received ginkgo biloba 240 mg/day for 14 days.

Measurements and Main Results. Plasma concentrations of cortisol, 11-deoxycortisol, 17α-hydroxyprogesterone, testosterone, dihydrotestosterone, dehydroepiandrosterone sulfate, sex hormone–binding globulin, androstenedione, and free testosterone, as well as free androgen index and combined concentrations of androsterone sulfate and epiandrosterone sulfate, were analyzed in all subjects before and after their 14-day course of ginkgo biloba. Ginkgo biloba did not significantly alter endogenous steroid levels compared with baseline values (p<0.05).

Conclusion. A 14-day oral administration of a widely used, standardized ginkgo extract at a generally advocated dosage of 240 mg/day did not significantly alter concentrations of major circulating steroids in men and women.

 
  Author(s) affiliations
 
1. The Departments of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, South Carolina.
Address reprint requests to John S. Markowitz, Pharm.D., Medical University of South Carolina, Children's Research Institute, Room 412, Laboratory of Drug Disposition and Pharmacogenetics, 173 Ashley Avenue, Charleston, SC 29425; e-mail: markowij@musc.edu.
2. Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina.
3. Steroid and Immunobiochemistry Laboratory, Canterbury Health Labs, Christchurch, New Zealand.
4. Surgery, Medical University of South Carolina, Charleston, South Carolina.
5. Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina.
6. Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina.